Logo

ESLA

Estrella Immunopharma, Inc.

ESLA

Estrella Immunopharma, Inc. • NASDAQ
$2.11 ▲ 12.23% (+0.23)
Market Cap $79.69 M
52w High $3.15
52w Low $0.73
Dividend Yield 0%
P/E -8.79
Volume 76.81K
Outstanding Shares 37.77M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $5.544M ▲ $-5.545M ▼ 0% $-0.15 ▼ $-5.544M ▼
Q1-2025 $0 $2.104M ▲ $-2.104M ▼ 0% $-0.058 ▼ $-2.104M ▼
Q4-2024 $0 $1.05M ▼ $-1.05M ▲ 0% $-0.029 ▲ $-1.05M ▲
Q3-2024 $0 $3.377M ▼ $-3.377M ▲ 0% $-0.093 ▲ $-3.377M ▲
Q2-2024 $0 $3.949M $-3.951M 0% $-0.11 $-3.949M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $1.317M ▲ $2.981M ▲ $9.075M ▲ $-6.095M ▼
Q1-2025 $421.473K ▼ $2.444M ▼ $4.275M ▲ $-1.831M ▼
Q4-2024 $916.916K ▼ $3.141M ▼ $2.997M ▲ $143.731K ▼
Q3-2024 $1.798M ▼ $3.735M ▼ $2.989M ▲ $746.286K ▼
Q2-2024 $4.165M $4.454M $180.701K $4.273M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-5.545M ▼ $-414.879K ▲ $0 $1.31M ▲ $895.121K ▲ $-414.879K ▲
Q1-2025 $-2.104M ▼ $-465.981K ▲ $0 $-29.462K ▼ $-495.443K ▲ $-465.981K ▲
Q4-2024 $-1.05M ▲ $-896.066K ▲ $0 $15.479K ▲ $-880.587K ▲ $-896.07K ▲
Q3-2024 $-3.377M ▲ $-2.217M ▼ $0 $-150.465K ▲ $-2.368M ▼ $-2.217M ▼
Q2-2024 $-3.951M $-291.513K $0 $-270.349K $-561.862K $-291.51K

Five-Year Company Overview

Income Statement

Income Statement Estrella is still a pure research company, not a commercial business yet. It has essentially no revenue, and its income statement is driven almost entirely by research and corporate expenses. Losses are modest in absolute terms but consistent, reflecting ongoing development work without any sales to offset costs. Earnings per share are negative and somewhat uneven year to year, which is typical for a small biotech as capital raises, share count changes, and one‑off items can move per‑share figures around even when the underlying business hasn’t changed much.

Balance Sheet

Balance Sheet The balance sheet looks very light, with minimal reported assets, little or no visible cash in this snapshot, no debt, and only a sliver of equity. In practical terms, this suggests a company heavily reliant on periodic external financing rather than on an established asset base or internal cash generation. The absence of debt reduces financial leverage risk, but the small equity base and very lean asset position highlight vulnerability: progress depends on continued access to capital markets or partners, and shareholders may face dilution as new funding is raised. The data here are also quite coarse, so the exact financial strength is somewhat opaque.

Cash Flow

Cash Flow Cash flows are negative from operations, which is exactly what you’d expect from a clinical‑stage biotech with no products on the market. The company appears to be burning cash on research, clinical trials, and overhead, with essentially no spending on large physical assets. Free cash flow is therefore also negative and closely tracks operating outflows. In this model, the lifeline is external funding—equity raises, grants, or partnerships—which are not detailed here but are essential to keep trials moving forward. The key financial risk is how quickly the company uses its cash versus how easily it can replenish it.

Competitive Edge

Competitive Edge Estrella’s competitive story rests far more on its science than on its current finances. Its ARTEMIS T‑cell platform aims to deliver safer and more controlled cell therapies than traditional CAR‑T, which could be a meaningful edge if confirmed in larger trials. Early clinical signs for its lead program, EB103, look encouraging on safety and response, and the focus on patient groups often excluded from standard CAR‑T gives it a more specialized niche where competition is thinner. The collaboration to extend its approach into solid tumors, an area where many others struggle, adds strategic breadth. At the same time, the company operates in a crowded, high‑stakes field dominated by much larger, well‑funded players, and its advantage is still unproven at scale. Regulatory, clinical, and commercialization hurdles remain substantial.

Innovation and R&D

Innovation and R&D Innovation is clearly the core asset here. The ARTEMIS platform is designed to mimic more natural T‑cell signaling, which could reduce severe side effects and improve durability of response, addressing key pain points of existing cell therapies. The ability to target proteins inside cancer cells, not just on their surface, is a notable scientific differentiator that could open up new treatment targets. The pipeline is layered: EB103 is in clinical development for certain blood cancers; EB104 is being readied to tackle resistance by hitting two targets at once; and the partnership using an oncolytic virus to “mark” solid tumors for attack is an example of creative platform extension. All of this is still in development, so the value of the R&D program hinges on future trial results, regulatory feedback, and the company’s capacity to fund and execute multiple programs in parallel.

Summary

Estrella Immunopharma is an early‑stage, science‑driven biotech with minimal current financial heft and no commercial products, but with a differentiated technology platform targeting a high‑need area in cancer treatment. The financial picture is simple: recurring losses, negative cash flow, and dependence on outside capital, with very little in the way of hard assets or ongoing revenue streams. The strategic picture is more complex and more promising on paper: a potentially safer, more flexible T‑cell technology; encouraging early clinical signals; a focus on underserved patient groups; and a roadmap that extends into both blood cancers and solid tumors. The main uncertainties revolve around clinical success, regulatory outcomes, competition from larger players, and the company’s ability to secure enough funding and partnerships to carry its programs through long, expensive development paths. Overall, this is a high‑uncertainty story where the scientific and clinical trajectory will matter far more than current financial results.

NEWS

November 3, 2025 · 8:00 AM UTC

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Read more

October 6, 2025 · 8:00 AM UTC

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Read more